<?xml version="1.0" encoding="UTF-8"?>
<p class="p">For curative or palliative care, several cost-effectiveness studies have been conducted on respiratory conditions, such as asthma interventions,
 <xref rid="b45-ehi-8-2014-043" ref-type="bibr" class="xref">45</xref>,
 <xref rid="b46-ehi-8-2014-043" ref-type="bibr" class="xref">46</xref> allergic rhinitis testing methods,
 <xref rid="b47-ehi-8-2014-043" ref-type="bibr" class="xref">47</xref> immunotherapy,
 <xref rid="b48-ehi-8-2014-043" ref-type="bibr" class="xref">48</xref> and drugs.
 <xref rid="b49-ehi-8-2014-043" ref-type="bibr" class="xref">49</xref>,
 <xref rid="b50-ehi-8-2014-043" ref-type="bibr" class="xref">50</xref> For example, the cost per QALY of treating grass allergen with GRAZAX
 <sup class="sup">®</sup> ranged between €12,930 and €18,263 in seven northern European countries.
 <xref rid="b49-ehi-8-2014-043" ref-type="bibr" class="xref">49</xref>
</p>
